Di Benedetto, B.: Quetiapine as antidepressant: a putative cellular mechanism through ERK1/2 activation and induction of GDNF Release in C6 Glioma Cells. Pharmacopsychiatry 44 (6), p. 288 - 288 (2011)

Di Benedetto, B.; Vogl, A.; Butz, E.; Refojo, D.; Rupprecht, R.: Astrocytes and neurons coordinate their responsiveness to antidepressant treatment to modulate synaptic plasticity. Pharmacopsychiatry 44 (6), p. 288 - 288 (2011)

Domschke, K.; Reif, A.; Weber, H.; Richter, J.; Hohoff, C.; Ohrmann, P.; Pedersen, A.; Bauer, J.; Suslow, T.; Kugel, H. et al.; Heindel, W.; Baumann, C.; Klauke, B.; Jacob, C.; Maier, W.; Fritze, J.; Bandelow, B.; Krakowitzky, P.; Rothermundt, M.; Erhardt, A.; Binder, E. B.; Holsboer, F.; Gerlach, A. L.; Kircher, T.; Lang, T.; Alpers, G. W.; Ströhle, A.; Fehm, L.; Gloster, A. T.; Wittchen, H. U.; Arolt, V.; Pauli, P.; Hamm, A.; Deckert, J.: Neuropeptide S receptor gene-converging evidence for a role in panic disorder. Molecular Psychiatry 16 (9), pp. 938 - 948 (2011)

Edgar, N. M.; Touma, C.; Palme, R.; Sibille, E.: Resilient emotionality and molecular compensation in mice lacking the oligodendrocyte-specific gene Cnp1. Translational Psychiatry 1, e42 (2011)

Filiou, M. D.; Teplytska, L.; Gormanns, P.; Reckow, S.; Zhang, Y.; Frank, E.; Kessler, M. S.; Nussbaumer, M.; Maccarrone, G.; Landgraf, R. et al.; Turck, C. W.: Anxiety and mitochondria: Insights from the -omics world. Pharmacopsychiatry 44 (6), p. 289 - 289 (2011)

Filiou, M. D.; Teplytska, L.; Otte, D. M.; Yilmaz, O.; Zimmer, A.; Turck, C. W.: Proteomic alterations in G72/G30 transgenic mice. Pharmacopsychiatry 44 (6), p. 289 - 289 (2011)

Gaali, S.; Kozany, C.; Hoogeland, B.; Klein, M.; Hausch, F.: Development of fluorescence polarisation assays for the immunophilins FKBP51/52 and Cyp40. Pharmacopsychiatry 44 (6), p. 290 - 290 (2011)

Gassen, N. C.; Han, Y.; Wochnik, G.; Holsboer, F.; Rein, T.: Functional impact of FKBP51 on cellular pathways. Pharmacopsychiatry 44 (6), p. 290 - 290 (2011)

Glas, J.; Seiderer, J.; Fischer, D.; Tengler, B.; Pfennig, S.; Wetzke, M.; Beigel, F.; Olszak, T.; Weidinger, M.; Göke, B. et al.; Ochsenkühn, T.; Folwaczny, M.; Müller-Myhsok, B.; Diegelmann, J.; Czamara, D.; Brand, S.: Pregnane X Receptor (PXR/NR1I2) Gene Haplotypes Modulate Susceptibility to Inflammatory Bowel Disease. Inflammatory Bowel Diseases 17 (9), pp. 1917 - 1924 (2011)

Gopalakrishnan, R.; Kozany, C.; Hoogeland, B.; Bracher, A.; Hausch, F.: FKBP ligands. Pharmacopsychiatry 44 (6), p. 291 - 291 (2011)

Grünecker, B.; Kaltwasser, S. F.; Sämann, P. G.; Wotjak, C. T.; Landgraf, R.; Czisch, M.: Basal cerebral activity in a mouse model of trait anxiety as revealed by in vivo manganese enhanced MRI and cytochrome-c oxidase staining. Pharmacopsychiatry 44 (6), p. 292 - 292 (2011)

Hartmann, J.; Wagner, K. V.; Hausch, F.; Rein, T.; Schmidt, U.; Touma, C.; Müller, M. B.; Schmidt, M. V.: The involvement of FK506-binding protein 51 (FKBP51) in the behavioural and neuroendocrine effects of acute and chronic stress. European Neuropsychopharmacology 21 (Suppl. 3), pp. S189 - S190 (2011)

Hartmann, J.; Wagner, K. V.; Liebl, C.; Wolf, M.; Scharf, S. H.; Wang, X. D.; Hausch, F.; Rein, T.; Schmidt, U.; Touma, C. et al.; Müller, M. B.; Schmidt, M. V.: The involvement of FKBP51 and FKBP52 in the behavioural and neuroendocrine effects of acute and chronic stress. Pharmacopsychiatry 44 (6), p. 294 - 294 (2011)

Hausch, F.: FBKP51 as a paradigm for translation and academic drug discovery. Pharmacopsychiatry 44 (6), p. 294 - 294 (2011)

Havla, J.; Gerdes, L. A.; Meinl, I.; Krumbholz, M.; Faber, H.; Weber, F.; Pellkofer, H. L.; Hohlfeld, R.; Kümpfel, T.: De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. Journal of Neurology 258 (9), pp. 1665 - 1669 (2011)

Heinzmann, J. M.; Knapman, A.; van Nieuwenhuijzen, P.; Tietze, L.; Touma, C.: Fluoxetine impacts hypothalamic-pituitary-adrenal axis regulation and changes stress-coping behaviour in mice selectively bred for extremes in stress reactivity. Pharmacopsychiatry 44 (6), p. 295 - 295 (2011)

Hennings, J. M.; Kohli, M. A.; Czamara, D.; Wolf, C.; Domschke, K.; Arolt, V.; Baune, T.; Horstmann, S.; Brückl, T.; Klengel, T. et al.; Menke, A.; Müller-Myhsok, B.; Ising, M.; Uhr, M.; Lucae, S.: BDNF and NTRK2 polymorphisms and antidepressant treatment outcome. Pharmacopsychiatry 44 (6), p. 295 - 295 (2011)

Herrmann, L.; Golub, Y.; Henes, K.; Ionescu, I.; Büll, D.; Holsboer, F.; Wotjak, C. W.; Schmidt, U.: Decreased expression of synaptic proteins in a mouse model of posttraumatic stress disorder. Pharmacopsychiatry 44 (6), p. 295 - 295 (2011)

Hiemke, C.; Baumann, P.; Bergemann, N.; Conca, A.; Dietmaier, O.; Egberts, K.; Fric, M.; Gerlach, M.; Greiner, C.; Gründer, G. et al.; Haen, E.; Havemann-Reinecke, U.; Sirot, E. J.; Kirchherr, H.; Laux, G.; Lutz, U. C.; Messer, T.; Müller, M. J.; Pfuhlmann, B.; Rambeck, B.; Riederer, P.; Schoppek, B.; Stingl, J.; Uhr, M.; Ulrich, S.; Waschgler, R.; Zernig, G.: AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44 (6), pp. 195 - 235 (2011)

Hoehn, D.; Czisch, M.; Spoormaker, V. I.; Schröter, M.; Goya-Maldonado, R.; Holsboer, F.; Sämann, P. G.: Resting state network alterations in major Depression. Pharmacopsychiatry 44 (6), p. 296 - 296 (2011)